The main aim of this study was to investigate a mixture of two poorly water-soluble active pharmaceutical ingredients (APIs): an angiotensin II receptor antagonist (valsartan) and a calcium channel blocker (amlodipine besylate), chosen in a fixed-dose, in order to obtain new polymeric nanoparticles (NPs) for cardiovascular diseases treatment. NPs were prepared via nanoprecipitation method using poly (D,L-lactide-co-glycolide) (PLGA) as matrix and Pluronic F127 as stabilizer. Three formulations were investigated with different ratios of AML:VAL:PLGA (1:16:5, 1:16:7.5 and 1:16:10). Particle size, polydispersity index and zeta-potential analyses were performed to characterize and optimize the formulation. The in vitro drug release study was determined by using a dialysis membrane method under sink conditions. All NPs loaded with both APIs showed nano-size, negative potential, a high homogeneity and a slow drugs release in physiological environment.

The main aim of this study was to prepare and characterize polymeric nanoparticles containing two cardiovascular active pharmaceutical ingredients: valsartan (VAL) and amlodipine besylate (AML). Six formulations were evaluated with different ratios of AML:VAL:PLGA (1:16:17, 1:16:34, and 1:16:51) and different stirring speed (1200 and 2400 rpm). Encapsulation efficiency (EE, %) and particle size analyses were performed to characterize and optimize the formulation. All loaded nanoparticles showed a high EE (%), nano-size, negative x-potential and a high homogeneity.